Literature DB >> 19530931

Enhancement of nasal absorption of calcitonin loaded in liposomes.

S L Law1, K J Huang, V H Chou, J Y Cherng.   

Abstract

Intranasal administration of calcitonin-containing liposomes in rabbits was investigated to evaluate the in vivo calcitonin absorption performance. Plasma calcitonin concentrations and calcium levels were measured and pharmacokinetic parameters were calculated. The bioavailability of calcitonin resulted from the intranasal delivery formulations demonstrated an order of calcitonin-containing positively charged liposomes > calcitonin-containing negatively charged liposomes > calcitonin solution. The significant enhancement of bioavailability of calcitonin for positively charged liposomes may be due to the charge interaction of positively charged liposomes with the negatively charged mucosa surface. Marked accumulation of positively charged liposomes was found on the negatively charged nasal mucosa surface. The retention of positively charged liposomes on the nasal mucosa resulted in an increase of residence time with high local concentration of calcitonin for increase of absorption.

Entities:  

Year:  2001        PMID: 19530931     DOI: 10.1081/LPR-100108460

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  3 in total

Review 1.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 2.  Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.

Authors:  Rasha Itani; Mansour Tobaiqy; Achraf Al Faraj
Journal:  Theranostics       Date:  2020-05-01       Impact factor: 11.556

Review 3.  COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.

Authors:  Valamla Bhavana; Pradip Thakor; Shashi Bala Singh; Neelesh Kumar Mehra
Journal:  Life Sci       Date:  2020-08-23       Impact factor: 5.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.